Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study

References

• Cancer Registry of Norway. Cancer in Norway 2018 - Cancer Incidence, Mortality, Survival and Prevalence in Norway. Oslo: Cancer Registry of Norway; 2019.
   Google Scholar
• Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from the global burden of disease study 2015. Br J Dermatol. 2017;177(1):134–140. doi:10.1111/bjd.1551028369739
   PubMed Web of Science ®Google Scholar
• Arnold M, de Vries E, Whiteman DC, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer. 2018;143(6):1305–1314. doi:10.1002/ijc.3152729659012
   PubMed Web of Science ®Google Scholar
• Berwick M, Buller DB, Cust A, et al. Melanoma epidemiology and prevention In: Kaufman HL, Mehnert JM, editors. Melanoma. Cham: Springer International Publishing; 2016:17–49.
   Google Scholar
• Robsahm TE, Karagas MR, Rees JR, Syse A. New malignancies after squamous cell carcinoma and melanomas: a population-based study from Norway. BMC Cancer. 2014;14(1):210. doi:10.1186/1471-2407-14-21024645632
   PubMed Web of Science ®Google Scholar
• Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Clin Investig Dermatol. 2003;120(2):217–223.
   Google Scholar
• Stenehjem JS, Veierod MB, Nilsen LT, et al. Anthropometric factors and cutaneous melanoma: prospective data from the population-based janus cohort. Int J Cancer. 2018;142(4):681–690. doi:10.1002/ijc.3108628983909
   PubMed Web of Science ®Google Scholar
• De Giorgi V, Gori A, Savarese I, et al. Role of BMI and hormone therapy in melanoma risk: a case–control study. J Cancer Res Clin Oncol. 2017;143(7):1191–1197. doi:10.1007/s00432-017-2387-528289899
   PubMed Web of Science ®Google Scholar
• Olsen CM. Reproductive factors and risk of melanoma: still unresolved. Br J Dermatol. 2019;181(2):239. doi:10.1111/bjd.1813631290145
   PubMed Web of Science ®Google Scholar
• Rota M, Pasquali E, Bellocco R, et al. Alcohol drinking and cutaneous melanoma risk: a systematic review and dose–risk meta-analysis. Br J Dermatol. 2014;170(5):1021–1028.24495200
   PubMed Web of Science ®Google Scholar
• Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med. 2013;3(9):a015487–a015487. doi:10.1101/cshperspect.a01548724003247
   PubMed Web of Science ®Google Scholar
• Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2016;11(2):332–343. doi:10.2215/CJN.0857081426170177
   PubMed Web of Science ®Google Scholar
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13. doi:10.1016/j.mce.2010.04.00520398732
   PubMed Web of Science ®Google Scholar
• Gjersvik P. Why is the high risk of skin cancer in organ transplant recipients declining? Br J Dermatol. 2019;181(5):879–880. doi:10.1111/bjd.1843231674666
   PubMed Web of Science ®Google Scholar
• Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8(62):106132–106142. doi:10.18632/oncotarget.2219029285320
   PubMedGoogle Scholar
• Fattouh K, Ducroux E, Decullier E, et al. Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study. Transpl Int. 2017;30(11):1172–1180. doi:10.1111/tri.1301128700114
   PubMed Web of Science ®Google Scholar
• Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017;153(3):296–303. doi:10.1001/jamadermatol.2016.492028097368
   PubMed Web of Science ®Google Scholar
• Green AC, Olsen CM. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. Acta Derm Venereol. 2015;95(8):923–927. doi:10.2340/00015555-214826012553
   PubMed Web of Science ®Google Scholar
• Vajdic CM, van Leeuwen MT, Webster AC, et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2297–2303. doi:10.1158/1055-9965.EPI-09-027819622722
   PubMed Web of Science ®Google Scholar
• Muellenhoff MW, Koo JY. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatolog Treat. 2012;23(4):290–304.21936704
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res. 2008;59(6):794–799. doi:10.1002/art.23716
   Web of Science ®Google Scholar
• Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate and melanoma-specific mortality. J Eur Acad Dermatol Venereol. 2019;33(3):e123–e125. doi:10.1111/jdv.1530530357928
   PubMed Web of Science ®Google Scholar
• Polesie S, Gillstedt M, Sonnergren HH, Osmancevic A, Paoli J. Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study. Br J Dermatol. 2017;176(6):1492–1499. doi:10.1111/bjd.1517027858996
   PubMed Web of Science ®Google Scholar
• Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate exposure and risk of cutaneous malignant melanoma: no evidence of a dose-response relationship. Acta Derm Venereol. 2018;98(9):888–895. doi:10.2340/00015555-298729972216
   PubMed Web of Science ®Google Scholar
• Ehmann LM, Tillack-Schreiber C, Brand S, Wollenberg A. Malignant melanoma during ustekinumab therapy of Crohn’s disease. Inflamm Bowel Dis. 2011;18(1):E199–E200. doi:10.1002/ibd.2187721987390
   PubMed Web of Science ®Google Scholar
• Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP. Melanoma associated with tumour necrosis factor-alpha inhibitors: a research on adverse drug events and reports (RADAR) project. Br J Dermatol. 2014;170(5):1170–1172. doi:10.1111/bjd.1277924328939
   PubMed Web of Science ®Google Scholar
• Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(7):787. doi:10.1001/jamadermatol.2020.130032432649
   PubMed Web of Science ®Google Scholar
• O’Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871–1874. doi:10.1126/science.111423316166520
   PubMed Web of Science ®Google Scholar
• Robbins HA, Clarke CA, Arron ST, et al. Melanoma risk and survival among organ transplant recipients. J Clin Investig Dermatol. 2015;135(11):2657–2665.
   Google Scholar
• Karagas MR, Cushing GL Jr., Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer. 2001;85(5):683–686. doi:10.1054/bjoc.2001.193111531252
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Mellemkjær L, Nielsen GL, et al. Non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst. 2004;96(9):709–711. doi:10.1093/jnci/djh11815126608
   PubMedGoogle Scholar
• Tseng HW, Huang WC, Lu LY. The influence of immunosuppressants on the non-melanoma skin cancer among patients with systemic lupus erythematosus and primary Sjogren’s syndrome: a nationwide retrospective case-control study in Taiwan. Clin Exp Rheumatol. 2019;37(6):946–952.31074727
   PubMed Web of Science ®Google Scholar
• Castellsague J, Kuiper JG, Pottegard A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European longitudinal lymphoma and skin cancer evaluation - JOELLE study). Clin Epidemiol. 2018;10:299–310. doi:10.2147/CLEP.S14644229559812
   PubMed Web of Science ®Google Scholar
• Dobos J, Kenessey I, Tímár J, Ladányi A. Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathol Oncol Res. 2011;17(3):729–734. doi:10.1007/s12253-011-9377-821455635
   PubMed Web of Science ®Google Scholar
• Bhakoo HS, Paolini NS, Milholland RJ, Lopez RE, Rosen F. Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma. Cancer Res. 1981;41(5):1695–1701.7214339
   PubMed Web of Science ®Google Scholar
• Berge LAM, Andreassen BK, Stenehjem JS, et al. Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case–control study. BMJ Open. 2019;9(2):e025246. doi:10.1136/bmjopen-2018-025246
   Web of Science ®Google Scholar
• Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer Prev. 2009;45(7):1218–1231. doi:10.1016/j.ejca.2008.10.037
   Web of Science ®Google Scholar
• Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86–94. doi:10.1111/j.1742-7843.2009.00494.x19961477
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for ATC Classification and DDD Assignment 2015. Norwegian Institute of Public Health; 2016.
   Google Scholar
• WHO. Collaborating centre for drug statistics methodology. Norwegian Institute of Public Health Available from: https://www.whocc.no/. Accessed 611, 2020.
   Google Scholar
• Pottegård A, Friis S, Christensen R, Habel LA, Gagne JJ, Hallas J. Identification of associations between prescribed medications and cancer: a nationwide screening study. EBioMedicine. 2016;7:73–79. doi:10.1016/j.ebiom.2016.03.01827322460
   PubMed Web of Science ®Google Scholar
• Felleskatalogen [Internett]. Oslo: Felleskatalogen AS. ATC-register, Antineoplastiske og immunomodulerende midler; 2020 Available from: https://www.felleskatalogen.no/medisin/atc-register/L04A. Accessed 326, 2020.
   Google Scholar
• Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Sørensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case–control study. Br J Cancer. 2008;99(9):1522–1528. doi:10.1038/sj.bjc.660468618813314
   PubMed Web of Science ®Google Scholar
• Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: photoallergic and phototoxic reactions. Clin Dermatol. 2016;34(5):571–581. doi:10.1016/j.clindermatol.2016.05.00627638435
   PubMed Web of Science ®Google Scholar
• Pottegard A, Friis S, Sturmer T, Hallas J, Bahmanyar S. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol. 2017.
   Web of Science ®Google Scholar
• Selvag E. Drugs and sun. Tidsskr nor Laegeforen. 2003;123(13–14):1860–1861.12830267
   PubMedGoogle Scholar
• Berge LAM, Andreassen BK, Stenehjem JS, et al. Use of antidepressants and risk of cutaneous melanoma: a prospective registry-based case-control study. Clin Epidemiol. 2020;12:193–202. doi:10.2147/CLEP.S24124932110111
   PubMed Web of Science ®Google Scholar
• Medhaug I, Olseth JA, Reuder J. UV radiation and skin cancer in Norway. J Photochem Photobiol B. 2009;96(3):232–241. doi:10.1016/j.jphotobiol.2009.06.01119628404
   PubMed Web of Science ®Google Scholar
• Robsahm TE, Tretli S. Cutaneous malignant melanoma in Norway: variation by region of residence before and after the age 17. Cancer Causes Control. 2001;12(6):569–576. doi:10.1023/A:101128791840511519765
   PubMed Web of Science ®Google Scholar
• Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47(17):2607–2617. doi:10.1016/j.ejca.2011.04.02321620689
   PubMed Web of Science ®Google Scholar
• Karagas MR, Zens MS, Stukel TA, et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control. 2006;17(1):11–19. doi:10.1007/s10552-005-0281-y16411048
   PubMed Web of Science ®Google Scholar
• Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol. 1993;22(6):1189–1192. doi:10.1093/ije/22.6.11898144304
   PubMed Web of Science ®Google Scholar
• Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35(5):782–800. doi:10.1002/sim.679326619806
   PubMed Web of Science ®Google Scholar
• R: A language and environment for statistical computing. [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2018.
   Google Scholar
• Ciechomska I, Legat M, Golab J, et al. Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies. Int J Cancer. 2005;117(1):59–67. doi:10.1002/ijc.2115315880533
   PubMed Web of Science ®Google Scholar
• Nihal M, Wu J, Wood GS. Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy. Arch Biochem Biophys. 2014;563:101–107. doi:10.1016/j.abb.2014.04.01924862567
   PubMed Web of Science ®Google Scholar
• Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, Venuta S. Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer. 2004;40(18):2829–2836. doi:10.1016/j.ejca.2004.08.01715571967
   PubMed Web of Science ®Google Scholar
• Rizvi SMH, Aagnes B, Holdaas H, et al. Long-term change in the risk of skin cancer after organ transplantation: a population-based nationwide cohort study. JAMA Dermatol. 2017;153(12):1270–1277. doi:10.1001/jamadermatol.2017.298429049612
   PubMed Web of Science ®Google Scholar
• Mérot Y, Miescher PA, Balsiger F, Magnenat P, Frenk E. Cutaneous malignant melanomas occurring under cyclosporin A therapy: a report of two cases. Br J Dermatol. 1990;123(2):237–239. doi:10.1111/j.1365-2133.1990.tb01852.x2400725
   PubMed Web of Science ®Google Scholar
• Pedersen EG, Pottegard A, Hallas J, et al. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol. 2014;21(3):454–458. doi:10.1111/ene.1232924330255
   PubMed Web of Science ®Google Scholar
• Kerensky TA, Gottlieb AB, Yaniv S, Au S-C. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf. 2012;11(1):121–139. doi:10.1517/14740338.2012.63350922074366
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol. 2005;141(7):861–864. doi:10.1001/archderm.141.7.86116027301
   PubMedGoogle Scholar
• Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–391. doi:10.1136/annrheumdis-2016-20928527307502
   PubMed Web of Science ®Google Scholar
• Banciu M, Schiffelers RM, Fens MHAM, Metselaar JM, Storm G. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Release. 2006;113(1):1–8. doi:10.1016/j.jconrel.2006.03.01916707187
   PubMed Web of Science ®Google Scholar
• DiSorbo DM, McNulty B, Nathanson L. Growth inhibition of human malignant melanoma cells by glucocorticoids. Cancer Res. 1983;43(6):2664–2667.6850583
   PubMed Web of Science ®Google Scholar
• Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006;12(10):3003–3009. doi:10.1158/1078-0432.CCR-05-208516707595
   PubMed Web of Science ®Google Scholar
• Herings RMC, Pedersen L. Pharmacy-based medical record linkage systems In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 2012:270–286.
   Google Scholar
• Matas AJ. What’s new and what’s hot in transplantation: clinical science ATC 2003. Am J Transplant. 2003;3(12):1465–1473. doi:10.1046/j.1600-6135.2003.00285.x14629276
   PubMed Web of Science ®Google Scholar
• Maiorino A, De Simone C, Perino F, Caldarola G, Peris K. Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy. J Dermatolog Treat. 2016;27(5):443–447. doi:10.3109/09546634.2015.113388226822468
   PubMed Web of Science ®Google Scholar
• NorPD. Statistics from the Norwegian prescription database. Norwegian Institute of Public Health; 2020 Available from: http://norpd.no/Prevalens.aspx. Accessed 819, 2020.
   Google Scholar